RVG TFA (Synonyms: RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA) |
Catalog No.GC26370
One-Click Copy Product Info
|
RVG TFA es un péptido derivado de la glicoproteína del virus de la rabia que se une a la subunidad α-7 del receptor nicotínico de acetilcolina (AchR) de las células neuronales
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1408311-03-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
RVG TFA es un péptido derivado de la glicoproteína del virus de la rabia que se une a la subunidad α-7 del receptor nicotínico de acetilcolina (AchR) de las células neuronales[1]. RVG es un péptido de 29 aminoácidos no tóxico (YTIWMPENPRPGTPCDIFTNSRGKRASNG) que puede mejorar la entrega de antígenos de Mycobacterium tuberculosis a las células presentadoras de antígenos (APCs)[2]. RVG se puede acoplar a medicamentos, siRNA o nanopartículas para lograr una administración específica al sistema nervioso central (CNS)[3, 4]. RVG puede servir como un ligando de orientación para vectores no virales (como liposomas o exosomas) para mejorar la eficiencia de la administración de genes [5]. RVG interactúa con los receptores del huésped, incluidos los receptores nicotínicos de acetilcolina (nAChRs), las moléculas de adhesión de células neuronales (NCAM), el receptor de neurotrofina p75 (P75NTR), el subtipo 2 del receptor de glutamato metabotrópico (mGlu2) e integrina β1 (ITGβ1) para iniciar la endocitosis viral en las células[6].
References:
[1] Shelukhina I, Siniavin A, Kasheverov I, et al. α7-and α9-containing nicotinic acetylcholine receptors in the functioning of immune system and in pain[J]. International Journal of Molecular Sciences, 2023, 24(7): 6524.
[2] Garnica O, Das K, Devasundaram S, et al. Enhanced delivery of Mycobacterium tuberculosis antigens to antigen presenting cells using RVG peptide[J]. Tuberculosis, 2019, 116: S34-S41.
[3] Wang Q, Cheng S, Qin F, et al. Application progress of RVG peptides to facilitate the delivery of therapeutic agents into the central nervous system[J]. RSC advances, 2021, 11(15): 8505-8515.
[4] Gao Y, Wang Z Y, Zhang J, et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain[J]. Biomacromolecules, 2014, 15(3): 1010-1018.
[5] Xie R, Wang Y, Burger J C, et al. Non-viral approaches for gene therapy and therapeutic genome editing across the blood–brain barrier[J]. Med-x, 2023, 1(1): 6.
[6] O’Brien B C V, Thao S, Weber L, et al. The human alpha7 nicotinic acetylcholine receptor is a host target for the rabies virus glycoprotein[J]. Frontiers in Cellular and Infection Microbiology, 2024, 14: 1394713.
| Cas No. | 1408311-03-4 | SDF | |
| Sinónimos | RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA | ||
| Formula | C141H217N43O43S2.xC2HF3O2 | M.Wt | 3266.62 (free base) |
| Solubility | H2O : ≥ 100 mg/mL | Storage | Store at -20°C,Sealed storage, away from moisture and light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 306.1 μL | 1.5306 mL | 3.0613 mL |
| 5 mM | 61.2 μL | 306.1 μL | 612.3 μL |
| 10 mM | 30.6 μL | 153.1 μL | 306.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)